Prostate cancer in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding prostate cancer

Canine prostate cancer is usually an aggressive cancer that can invade the urinary tract and spread to lymph nodes, lungs or bone. Because the prostate sits in a difficult location, complete surgical removal is often not straightforward. Maintaining urine flow and understanding the extent of disease are immediate practical priorities.

What does the prognosis look like?

Published outcomes vary widely because treatment groups are very different. The typical survival time was about 3 months in one multi-hospital medical-treatment group and about 18 months in a selected group receiving definitive radiation. That does not mean radiation gives every dog that result. Extent of disease, ability to maintain urine flow and whether effective local treatment is possible determine which comparison is relevant.

What matters next

Urination and comfort come first. Difficulty passing urine can require an intervention before the long-term cancer plan. Once your dog is stable, define how far the tumor extends around the prostate and urethra and whether it has spread, because those findings determine which local and systemic options are realistic.

Where are you now?

Urination is difficult or blocked

Urinary obstruction can become urgent. Restoring urine flow may need to come before the longer-term cancer plan, and interventional procedures can sometimes be part of that strategy.

There is pelvic or bone pain

Prostatic carcinoma can invade locally and spread to bone. Make pain control explicit and ask whether imaging the painful area would change radiation or systemic treatment.

Treatment has already started or disease has spread

Keep a clear record of NSAIDs, chemotherapy, radiation, and response. Prior treatment and metastatic sites affect what systemic or local options remain reasonable.

If you are waiting for oncology

Urinary obstruction and pain can become the immediate problem. While waiting for oncology, monitor urine flow closely and ask whether local imaging, renal values or an interventional procedure is needed before systemic treatment decisions.

Questions to ask your oncologist

Is urine flow threatened, and do we need an intervention before cancer treatment?
Where has the disease spread, including nodes, lungs or bone?
What local and systemic treatments are realistic for this extent of disease?

How the diagnosis may appear in the record

Reports may use prostatic carcinoma, adenocarcinoma, or urothelial carcinoma involving the prostate; these are not automatically interchangeable. Imaging and cytology or biopsy should clarify the likely origin when possible. Record involvement of the urethra, bladder, regional nodes, lungs, and bone.

Changes to watch for at home

Watch the urine stream, frequency, straining, blood in urine, difficulty defecating, pelvic or back pain, hind-limb lameness, and appetite. Inability to pass urine, severe pain, vomiting with urinary difficulty, or sudden weakness needs urgent assessment.

How it is usually treated

Treatment is usually multimodal because complete surgical removal is difficult in many dogs. NSAIDs, chemotherapy and radiation can all be part of the plan. Procedures to keep urine flowing may be necessary when the tumor narrows the urethra, and local treatment is chosen according to anatomy and metastatic stage.

What can affect treatment choices

Urinary obstruction, local invasion, pain, kidney function and metastatic spread strongly affect treatment. Whether radiation or an interventional procedure can safely control the local disease is often as important as the systemic plan.

Tests that may matter

Imaging should define the prostate, urethra, bladder and regional lymph nodes and look for metastatic disease when appropriate. Kidney values matter when urine flow is compromised. If tissue confirmation is needed, the safest sampling method should be chosen based on anatomy and whether the result will change treatment.

Treatment options available now

4 options currently in our catalog.

Check eligibility

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

PSMA-MMAE-Pc413 theranostic plus laser for canine prostatic cancer

University of Pennsylvania School of Veterinary Medicine · USA

Location

Penn Vet Ryan Veterinary Hospital, 3900 Spruce St, Philadelphia, PA 19104

Study details

Current Penn Vet clinical trial

What is being offered: Targeted investigational PSMA ligand carrying MMAE and a photosensitizer, combined with laser photodynamic therapy; intended for local and metastatic canine prostatic cancer.

Who may qualify: Active tumor required; Prostatic cancer; Prostatic diagnosis at screening

Costs / coverage: 🟢 Fully funded study procedures. The study covers specified diagnostics after enrollment, theranostic infusions, laser treatment, hospitalization and study rechecks including imaging and laboratory testing.

Contact: Penn Vet VCIC — 215-573-0302; vcic@vet.upenn.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →